[Treatment of erectile dysfunction using intracavernous pharmacotherapy]

Area of Science:

• Urology
• Andrology
• Pharmacology

Background:

• Intracavernous injection of vasodilators represents a significant advancement in diagnosing and treating erectile dysfunction (E.D.).
• Over 15 years of clinical experience demonstrates efficacy rates exceeding 85% for these treatments.
• The high success rate suggests that many E.D. cases stem from smooth muscle relaxation failure.

Purpose of the Study:

• To provide a comprehensive overview of the diagnostic and therapeutic applications of intracavernous vasodilating drugs.
• To review existing literature and present personal series data on the efficacy, indications, contraindications, and side effects of these compounds.

Main Methods:

• Literature review of intracavernous vasodilator treatments for erectile dysfunction.
• Analysis of personal clinical series data regarding efficacy and safety.
• Evaluation of specific compounds like Alprostadil (PGE1) and combinations (phentolamine, papaverine, VIP).

Main Results:

• Alprostadil (PGE1) injection shows over 70% efficacy and safety, enhancing patient quality of life with minimal side effects.
• Combination therapies (e.g., phentolamine + PGE1, papaverine + phentolamine) are effective when PGE1 alone is insufficient or causes pain.
• The phentolamine + VIP combination demonstrates promising results.

Conclusions:

• Intracavernous vasodilators, especially Alprostadil (PGE1), are a first-choice treatment for impotence due to high efficacy and safety.
• Careful patient selection, including basic diagnostics and counseling, is essential before initiating intracavernous therapy.
• Adequate patient training and medical follow-up are crucial for successful treatment outcomes.